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Chemically mediated sexual communication in humans has been largely neglected 
due to its non-conscious and relatively concealed nature. However, menstrual cycle 
synchronisation, puberty onset in young pre-pubertal girls exposed to their 
stepfather, and consanguinity avoidance suggest a function in the physiological 
regulation of sexual and reproductive behaviour in humans. These phenomena are 
related to activation of the limbic system by pheromones. Based on sexually 
dimorphic activation of brain hypothalamic areas and the control of body 
temperature via the hypothalamus, our hypothesis is that human sexual 
pheromones can induce thermal effects that can be revealed by high-resolution 
thermal infrared imaging. Here we show that in women, male sexual pheromones 
induce thermal effects that are linked to the ovarian cycle. These findings suggest a 
dramatic influence of pheromones on human sexual and reproductive behaviour 
through neuroendocrine brain control, established on the plesiomorphic nature of 
chemical communication across species. 
Pheromones are striking species-specific chemosignals that control a wide range of 
social behaviours in animals (Karlson and Luscher, 1959). These are otherwise 
unimportant chemical compounds that range in structure from volatile small molecules 
2 
to peptides and steroids, and they have been selected through evolution and combined in 
individual-specific concentrations within species (Wyatt, 2009). In both animals and 
humans, the pheromonal identity of any given individual has a decisive role in the 
sexual and reproductive behaviour relating to their genetics identification, providing 
avoidance of consanguinity (Roberts and Little, 2008). However, pheromone-mediated 
sexual communication in humans has not been investigated comprehensively, generally 
because of its non-conscious, concealed nature and the neglected functions of the 
vomeronasal organ (Jacob et al, 2001b; Monti-Bloch et al., 1998; Meredith, 2001; 
Wysocki and Preti, 2004). Indeed, it is commonly believed that pheromonal 
communication in mammals belongs to a unique and specialised pathway, the 
vomeronasal system, and that the main olfactory epithelium is responsible exclusively 
for sensing common odours (Keverne, 2004).  
More recently, however, a new perspective in pheromone perception has emerged 
following the discovery of a new class of evolutionarily preserved chemoreceptors, the 
trace amine-associated receptors, that are involved in the detection of pheromonal cues 
(Liberles and Buck, 2006). These findings support the involvement in the human 
chemo-sexual communication of a pathway that is mediated via the main olfactory 
system (Shepherd, 2006; Savic et al, 2009). 
Despite these considerations, in human, pheromones can elicit sexually dimorphic 
activation of hypothalamus–amygdale areas, independent of whether they are sensed 
through the vomeronasal system or the main olfactory system, or both (Savic et al, 
2000; Savic et al, 2001; Savic and Lindström, 2008; Brancucci et al, 2008). This 
resembles a plesiomorphic plan of the mammalian pheromonal perception pathway, as 
has been shown in rodents, which show sexually dimorphic neuronal activation at 
multiple levels (Segovia and Guillamon, 1996; Keverne, 2004; Dean et al., 2004). 
Moreover, pheromones can regulate the physiology and behaviour of animals and 
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humans, as seen by menstrual cycle synchronisation and the Vandenberg effect, which 
involves the female control of sperm competition and the onset of puberty (McClintock, 
1971; Ellis and Garber, 2000). These findings reveal the evolutionary roots and the 
chemical nature of sexual function in humans. 
Of particular interest, human pheromones activate the hypothalamus (Swaab et al, 
2001; Savic et al, 2001; Wyart et al, 2007), which controls the autonomic nervous 
system (ANS), a key structure in sexual arousal, sex-hormone release, reproductive 
behaviour, and body-temperature regulation. Thus, autonomic parameters can vary in 
humans exposed to pheromones (Monti-Bloch et al, 1998; Bensafi et al, 2004a, b; Jacob 
et al., 2001b). In particular, androstadienone (4,16-androstadien-3-one), a sex-steroid-
derived compound, can induce dose-dependent and gender-specific non-conscious 
effects on ANS responses and on peripheral physiological activity and mood (Jacob et 
al., 2001b; Bensafi et al, 2004a,b). A noticeable effect here is the variation of hedonic 
perception across the ovarian cycle that is associated with another putative human 
pheromone, androstenone (5-α-androst-16en-3α-on), which elicits neutral or unpleasant 
smell sensations according to the ovulatory and non-ovulatory periods, respectively 
(Hummel et al 1991; Grammer, 1993). Similarly, the preferences of women for male 
faces, voices, masculinity and behavioural displays, and the neuromodulation of the 
reward system depend on the phases of the ovarian cycle (Dreher et al, 2007; Jones et 
al, 2008; Gangestad and Thornhill, 2008). Although odorant perception and olfactory 
thresholds have been associated with the ovarian cycle and the hormone status, nothing 
has been specifically established with respect to pheromone perception and its relation 
to the ovarian cycle and hormone status (Navarrete-Palacios et al, 2003; Doty and 
Cameron, 2009). It has also been demonstrated that ovarian hormones can control 
sexual arousal and that women present a sexual arousal peak around ovulation (Adams 
et al, 1978; Matteo and Rissman, 1984; Wallen, 1990).  
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Therefore, even 50 years after their discovery, the open question remains whether 
sexual and reproductive behaviour in humans depends on interactions between these 
sexual pheromones and the hormone status. To investigate this question, we compared 
the dynamics of facial cutaneous temperature in women during their ovulatory versus 
non-ovulatory conditions, while they were exposed to androstadienone. Indeed, facial 
cutaneous temperature is controlled by the ANS, and it might thus represent a 
fundamental communication tool for sexual arousal (Prause and Heiman, 2009; 
Kukkonen et al., 2009). 
We used here high-resolution thermal infrared imaging to monitor the patterns and 
time-courses of facial temperature (Pavlidis et al, 2002; Merla and Romani, 2007; 
Shastri et al, 2009). The other ANS parameters that were recorded included pulse rate, 
breathing rate, galvanic skin response, and palm temperature, as relevant system-
response controls.  
These signals were recorded across three experimental phases: adaptation, during 
which time the women adapted to the experimental set-up while being exposed to the 
placebo (double-distilled water); stimulation, with the women exposed to 
androstadienone; and recovery, with the women again exposed to the placebo. In the 
control experiments, the placebo was instead administered during all three of these 
phases. Baseline normalisation and trend corrections were then applied to analyse the 
time-courses of the temperature curves.  
Figure 1 shows representative high-resolution images of the facial temperature 
changes induced during placebo exposure and exposure to the pheromone 
androstadienone in ovulatory and non-ovulatory women under the adaptation (AP), 
stimulation (SP) and recovery (RP) periods. These temperature modifications showed 
region-based amplitude variations, within a range of 28 °C to 37 °C.  
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The exposure of the ovulatory and non-ovulatory women to the pheromone 
produced marked differences in both the spatial patterns (Fig. 1) and time-courses (Fig. 
2) of the whole-face temperatures across the experimental phases. For these average 
group temperatures, during the stimulation and recovery periods the whole-face 
temperatures increased with the ovulatory women and decreased with the non-ovulatory 
women (Fig. 2). Indeed, for androstadienone exposure as recovery period vs. 
stimulation period, there was a significant continuous increase in the ovulatory women 
(p <0.001; paired t-test) and a significant continuous decrease in the non-ovulatory 
women (p <0.05; paired t-test), compared to placebo exposure, where no changes were 
seen. This group analysis thus highlighted the dramatic influence of the ovulatory 
condition on the temperature time-course induced by exposure to the pheromone. 
When pixel-by-pixel subtraction algorithms were applied to these thermal image 
series (after movement correction and image re-alignment), the representative high-
resolution subtraction image series shown in Figure 3 highlighted the temperature 
differences in specific facial regions across the ovulatory conditions and time-course 
phases. In particular, with the ovulatory women, androstadienone exposure induced 
scattered-shaped increases in the temperatures for the nose, forehead, lachrymal gland 
and peri-oral region. Conversely, androstadienone administration with the non-
ovulatory women caused scattered decreases in the temperatures in these same regions. 
The control (placebo) exposure produced only a generalised cooling of the face 
temperature, with this placebo trend adjusted for in the following data analysis.  
These findings prompted us to further investigate the time-courses in these 
specific localised facial regions, which correspond to responsive areas for 
neurophysiological activation described in the literature (Pavlidis, 2002; Shastri, 2009). 
Figure 4 shows the group-averaged temperatures across the full time-courses for the 
pheromone (and placebo) exposure periods for six specific regions of interest (ROIs): 
6 
the right and left lachrymal regions and cutaneous projections of the corrugator muscles, 
and the forehead and the nose. The temperatures across these ROIs showed essentially 
similar behaviours. In the ovulatory women, exposure to androstadienone initially 
showed little change from placebo during the exposure (stimulation) period, except for a 
significant activation peak more specifically for the right lachrymal region and the nose 
(p <0.05 and p <0.01, respectively). Then upon removal of androstadienone, there were 
rises in the temperatures across these ROIs for the duration of the recovery period. In 
contrast, in the non-ovulatory women, exposed to androstadienone, there was an almost 
immediate cooling down of all of these facial regions (except for the nose) that 
generally continued through the recovery period. Paired t-tests for phase-to-phase 
comparisons highlighted the significant differences in the temperature variations across 
these ROIs, which were not seen under placebo administration or during the adaptation 
phase (Table 1).  
The largest variations here were seen for the nose, the temperature of which 
appeared to show a significant late activation peak during the recovery phase following 
androstadienone exposure in both the ovulatory and non-ovulatory women (p <0.001 for 
both), as also seen for the forehead region with the non-ovulatory women (Fig. 4).  
Figure 5 shows the time variations of the group-averaged autonomic parameters 
recorded, following baseline normalisation and placebo-trend correction. Here, the palm 
temperature reproduced the nose and forehead temperature time-courses, thus 
suggesting a systemic effect of androstadienone on temperature control. Moreover, in 
the ovulatory women, the palm temperature appeared to be the most responsive 
parameter to androstadienone administration. Similarly, the galvanic skin response 
showed a dramatic increase in the ovulatory women during the recovery phase.  
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In particular, the pulse rate also significantly increased with androstadienone 
exposure under both ovulatory and non-ovulatory conditions (Fig. 4). These were seen 
as higher values with the ovulatory women during the exposure, although during the 
recovery phase, the pulse rates of the non-ovulatory women increased such that they 
matched those of the ovulatory women at the end of the observation period (Fig. 4). 
Finally, the breathing rates significantly decreased with androstadienone administration 
under both the ovulatory and non-ovulatory conditions, with a larger decrease seen 
during the androstadienone exposure for the non-ovulatory women. Again, during the 
recovery phase after androstadienone exposure, the breathing rates of the ovulatory and 
non-ovulatory women reached similar final values, while remaining significantly lower 
than their control values.   
In summary, the androstadienone administration appears to activate different ANS 
responses according to the physiological, ovulatory versus non-ovulatory, conditions of 
these women. These ANS responses appear to resemble antagonistic parasympathetic–
sympathetic-like effects, which might be responsible for the scattered or oscillatory 
behaviour found on both the spatial and time patterns of these temperature changes. 
Thus, both of these systems respond to androstadienone, but to different levels that 
depend on the physiological status of the woman. 
The sex-specific effects of androstadienone on the ANS and on mood that are 
reported in the literature are generally not very consistent across studies. Indeed, both 
sympathetic-like and parasympathetic-like effects have been reported in women (Jacob 
et al., 2001a; Grosser et al., 2000). Furthermore, the time-courses of the responses to 
exposure to androstadienone range across studies, from about 6 min, to 30-40 min, and 
up to more than 2 h (Jacob and McClintock, 2000; Grosser et al., 2000; Bensafi et al., 
2003). These discrepancies might reflect the various methodological approaches and the 
dose-dependent effects of the ANS responses that are seen between the sexes: at higher 
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concentrations, androstadienone has sympathetic-like effects in women, and 
parasympathetic-like effects in men (Bensafi et al., 2003; Bensafi et al., 2004b). 
Incongruities across these studies can also be ascribed to pheromone solvent and 
stimulus interactions, or to sexual differences (Wysocki et al, 2009). However, these 
data can be explained by the action of two hormones, as androgens and oestrogens, that 
separately stimulate antagonistic parasympathetic and sympathetic systems, resulting in 
synergistic effects on libido and sexual arousal at different levels in both men and 
women.  
Such sexual arousability is related to a natural asymmetric balance of hormones 
that can induce ‘lopsided’ sympatho-parasympathetic effects. This asymmetric balance 
of hormones is the more functional relationship between the two autonomic 
components, which act agonistically on the parasympathetic and sympathetic centres 
(Motofei and Rowland, 2005). At the same time, none of these previous studies have 
shown differences between women and across their physiological/ hormone status. 
These different responses in women might be related to the hormonal cycle being 
ultimately responsible for changes in facial appearance (Law Smith et al, 2006), mood 
(Jacob et al., 2001a; Bensafi et al, 2004a,b) and sexual arousal (Matteo and Rissman, 
1984), and for neurobiological and neurofunctional modulation of the reward systems 
(Dreher et al, 2007). Furthermore, the increased availability, receptivity and desire that 
can occur during a woman’s ovulatory period might have arisen from the evolutionary 
pressure to facilitate procreation.  
Different techniques and methodological approaches have established that 
androstadienone elicits mood alterations, pulsatile secretion of luteinising hormone, 
high level of cortisol, specific brain-region activation, and ANS responses (Grosser et 
al., 2000; Savic et al., 2001; Jacob et al., 2001a, 2002; Preti et al, 2003, Bensafi et al., 
2003, 2004; Wyart et al, 2007; Savic and Lindström, 2008). In particular, electrodermal 
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activity is considered a responsive indicator of autonomic sympathetic arousal 
(Critchley, 2002; Bensafi et al., 2002), while skin temperature has been reported as a 
parasympathetic indicator (Jacob et al., 2001a, b). Finally, measures such as heart rate 
and respiration activity are considered more variable in these studies (Bensafi et al., 
2004b). However, wide discrepancies in the autonomic nervous responses subsequent to 
androstadienone exposure have been reported as effects that appear not to be related to 
physiological status (Grosser et al., 2000; Jacob et al., 2001a; Bensafi et al., 2004b). 
One aspect of our data shows changes in the rates and time-courses of the 
autonomic parameters recorded (galvanic skin response, palm temperature, pulse rate, 
breathing rate). These modifications are in harmony with the physiological status of the 
women exposed to androstadienone. Furthermore, our results stress that although both 
of the ANS systems are antagonistically activated by androstadienone, the activation is 
strongly linked to the physiological hormone status, which results in agonistic effects on 
sexual and reproductive behaviour.  
Here, we have focussed our evaluations on the effects of the physiological 
conditions of these women during (and after) their exposure to androstadienone by 
measuring their facial temperatures using high-resolution thermal infrared imaging. This 
technique demonstrates that exposure to androstadienone elicits different physiological 
responses that are mediated by activation of the ANS and that appear to result in both 
sympathetic-like and parasympathetic-like effects that are linked to hormone status. 
Androstadienone increased facial temperature in the ovulatory women, priming 
scattered patterns of temperature variations. Conversely, androstadienone reduced the 
superficial skin temperature of the face in the non-ovulatory women. This is in 
agreement with the physiological mechanisms of sexual arousal, which are reinforced 
when the sympathetic and parasympathetic systems are simultaneously activated to 
different degrees. In women, opposite hormonal asymmetries would induce opposite 
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sympatho-parasympathetic sexual asymmetries, such that general sensation and arousal 
are linked to the parasympathetic sexual system, while the local erogenous sensations 
are linked to the sympathetic system. In summary, the strong–weak balance of these two 
classes of hormones generates concomitant but asymmetric functioning of the 
sympatho-parasympathetic systems during sexual arousal (Motofei and Rowland, 2005). 
This autonomic balance can be elicited with hormones and/or modulated by 
pheromones, to reach the activation levels of each of the autonomic systems.  
Furthermore, the asymmetric functioning of the sympatho-parasympathetic 
systems is highlighted by comparing these androstadienone effects with respect to the 
hormone status of the woman, as ovulatory versus non-ovulatory. Here, 
androstadienone appeared to cause a general thermal increase in the ovulatory women 
that was amplified in localised regions. These antagonistic effects resulted in 
regionalised oscillations of the temperatures in specific scattered patterns. Moreover, 
thermal fluctuations that suggest a double heat-peak response to androstadienone were 
detectable: an early response over the first few minutes of activation that is in agreement 
with previous studies (Jacob and McClintock, 2000), and a delayed response that is 
compatible with middle-to-late responses (Grosser et al., 2000; Bensafi et al., 2003).  
Even though we did not specifically investigate late responses, the behaviour seen 
resembles a two-fold pheromone effect of androstadienone. In ovulating woman, 
androstadienone would act as a releaser pheromone, as represented by the early peak. 
Androstadienone can then operate as a modulator pheromone, as characterised by the 
late peak (McClintock, 2000). This dual action allows us to speculate on the activation 
of specific patterns of sexual and reproductive behaviour according to the ovulatory 
condition, at least in terms of sexual arousal. In contrast, with the non-ovulatory 
condition, only the modulator effect of androstadienone was preserved, as represented 
by the late peak. Early activation was also seen here, although, in contrast, it resulted in 
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a temperature decrease, which could represent a negative releaser effect to avoid sexual 
and reproductive behaviour. 
These thermal fluctuations due to androstadienone exposure and their 
physiological effects across the menstrual cycle are congruent with variations in other 
autonomic parameters. As already suggested for olfactory perception, around ovulation, 
women recognize male odour as a pleasant smell, with the tendency thus to make 
contact with a potential partner. Conversely, in a non-ovulatory period (when there is 
less chance of pregnancy), the chemosignals that respond to the presence of a male can 
evoke unpleasant sensations in women (Watanabe et al, 2002). Moreover, these 
differences in autonomic responses are not linked to variations in olfactory thresholds. 
Pheromone perception appears to be constant across hormone status (Hummel et al, 
1991), while the response to this stimulus is strikingly dependent on hormone status. An 
evolutionary hypothesis also comes from our thermal data, which is further supported 
by these results of autonomic responses to non-conscious perception of the male sexual 
pheromone: the pheromone can elicit specific neuroendocrine activation that regulates 
sexual and reproductive behaviour.  
A new expanding scientific concept is that women have not lost oestrus 
(Gangestad and Thornhill, 2008). Our findings support the evidence that when in the 
fertile periods of their cycles, women are sexually attracted by physiological signals, 
such as pheromones. Through our ancestral evolution, pheromones were ‘designed’ for 
the assessment of predisposed displays of the genetic/ zoological quality of a mate, 
which we have shown still to be the case here. Thus dual sexuality of women has been 
hypothesised through the course of human evolution (Gangestad and Thornhill, 2008): 
the oestrus phase, which is related to the female sexual choice for good genes for their 
offspring, and the non-fertile phase, in which sexual and reproductive behaviour reduce 
male aggression towards offspring by uncertainties over paternity or as a form of 
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grooming for pair-bonding and couple reinforcing. These appear to be further supported 
by our findings. 
Today, now 50 years after the discovery of pheromones (Karlson and Luscher, 
1959), investigations into the influence of chemical communication on human sexual 
and reproductive behaviour are unveiling the evolution of its plesiomorphic nature. 
  
Methods 
Fourteen healthy women (mean age, 23 ±3 years) were enrolled in this study. The 
exclusion criteria were for an irregular hormonal cycle, use of contraceptive pills, 
smoking, alcohol or drug consumption, impaired sense of smell, homosexuality, any 
overt pathology or disease, or recent clinical surgery or anaesthesia. The women all 
provided written informed consent for participation in the study, which was performed 
in agreement with the ethical standards of the Helsinki Declaration, 1964, and approved 
by the local Human Board Review and Ethical Committee. Potential participants were 
a-priori tested for general olfactory perception and thresholds according to the 
Connecticut Chemosensory Clinical Research Centre test.  
Androstadienone (Steraloids, Inc., Newport, RI) was used in its odourless volatile 
crystalline form (1 ×10-3 g/vial), to avoid problems linked to solvents and 
concentrations (Bensafi et al, 2004; Savic et al, 2001). The hidden vials that contained 
either placebo or androstadienone were changed for each woman for each session, with 
the contents of all of the vials later confirmed by gas chromatography. Subjects rested in 
comfortable supine position during the experiments, which were performed at the same 
time of the day in order to avoid possible circadian effects.  
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The data were analysed using paired t-tests within subjects (statistical significance 
threshold, p <0.05), comparing conditions (ovulatory vs. non-ovulatory) and stimuli 
(androstadienone vs. placebo) through each experimental phase (adaptation, stimulation 
and recovery). 
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Figure 1. High-resolution infrared thermography facial images  
The women underwent a total of four measurement sessions: two sessions 
(control and experimental) for each ovulatory condition (ovulatory, OV; non-
ovulatory, NOV). Each woman was randomly assigned their measurement 
session sequences. Ovulatory status was determined according to urinary 
concentrations of luteinising hormone, using a commercial test kit (Clearplan, 
Schering spa). Each woman followed a series of preparatory standardisation 
procedures for thermal imaging (Merla, 2007) and a 20-min acclimatisation 
period in the climate-controlled measurement room (23 ±1 °C; 55%-60% 
relative humidity; no direct ventilation). The facial thermal imaging was 
performed using a 320×240 SC3000 QWIP Flir camera (NETD = 0.04 °C and 
30 °C; sampling rate, 25 full frames/s). Representative thermal images are 
shown for placebo (Ctrl) and androstadienone (AND) exposure across the 
blinded experimental periods: 5-min adaptation phase (AP), with exposure to 
placebo (double-distilled water); 10-min stimulation phase (SP), with exposure 
to placebo or androstadienone (control and experimental, respectively); and 20-
min recovery phase (RP), with exposed to placebo again. A false-colour 
temperature scheme is used for visualisation of the thermal effects (see inset).  
 
Figure 2. Group-averaged normalised facial skin temperatures 
The thermal image time series were re-aligned, corrected for movement 
artefacts, and processed according to experimental group using in-house-
developed Matlab routines. The temperature curves in the control experiments 
showed linear drift for the women for both their ovulatory and non-ovulatory 
conditions. This trend appeared due to the resting supine position maintained 
20 
by the women during the recording sessions. These linear control trends were 
therefore removed from the temperature curves, with the normalised 
temperatures (TN) shown for the ovulatory and non-ovulatory women for 
placebo (Ctrl) and androstadienone (AND) exposure across the experimental 
adaptation (AP), stimulation (SP) and recovery (RP) periods. The ovulatory and 
non-ovulatory temperatures for the androstadienone exposure during the 
stimulation and recovery phases are significantly different from the placebo 
exposure (p<0.05, p<0.001, respectively; paired t-tests).  
 
Figure 3. Pixel-by-pixel temperature subtraction  
Representative pixel-by-pixel temperature subtractions of the thermal images 
for the ovulatory (OV) and non-ovulatory (NOV) women for placebo (Ctrl) and 
androstadienone (AND) exposure across the experimental adaptation (AP), 
stimulation (SP) and recovery (RP) periods. A false-colour temperature scheme 
is used for visualisation of the thermal effects (see inset). 
 
Figure 4. Regional group-averaged normalised facial skin temperatures 
After movement correction and image re-alignment, the temperatures of the 
ROI were adjusted for baseline and normalised (TN). Comparisons are shown 
for the ROI group thermal image series in the ovulatory and non-ovulatory 
women for placebo (Ctrl; for clarity, only non-ovulatory placebo is shown) and 
androstadienone (AND) exposure across the experimental adaptation (AP), 
stimulation (SP) and recovery (RP) periods. Facial regions: lachrymal, right (Lr), 
left (Ll); corrugator muscle, right (Cr), left (Cl); forehead (F), and nose tip (N). 
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With the ovulatory women, Lr and N show an early response peak with 
androstadienone and a delayed peak during recovery, the latter of which is also 
seen for the non-ovulatory women for Ll, Cl, F and N. 
 
Figure 5. Group-averaged autonomic parameters 
The autonomic parameters (pulse rate, breathing rate, galvanic skin response 
[GSR] and palm temperature) were recorded simultaneously with the facial 
thermal imaging (ADInstruments ML870 PowerLab 8/30). The GSR and palm 
temperature autonomic parameter curves were adjusted for baseline and 
normalised (μSN and TN, respectively), with pulse rates and breathing rates 
unadjusted. Comparisons are shown for these autonomic parameters in the 
ovulatory and non-ovulatory women for placebo (Ctrl; for clarity, only non-
ovulatory placebo is shown) and androstadienone (AND) exposure across the 
experimental adaptation (AP), stimulation (SP) and recovery (RP) periods. In 
autonomic parameters result statistical differences when pheromone is applied 
(see table 1). 
 
Table 1. Paired t-test results for the significance of conditions (ovulatory 
vs. non-ovulatory) and stimulus (androstadienone vs. placebo) across the 
experimental phases, and according to the recorded parameters. 
 Adaptation Stimulation Recovery 
Parameter ovulatory  
versus 
non-
ovulatory 
androstadienone 
versus 
placebo 
ovulatory  
versus 
non-
ovulatory 
androstadienone 
versus 
placebo 
ovulatory  
versus 
non-
ovulatory 
androstadienone 
versus 
placebo 
Lachrymal, right ns ns ** ** ** ** 
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Lachrymal, left ns ns ** ** ** ** 
Corrugator 
muscle, right 
ns ns ** ** ** ** 
Corrugator 
muscle, left 
ns ns ** ns ns ** 
Forehead ns ns ** ns ** ** 
Nose ns ns * * ** ** 
Galvanic skin 
response 
ns ns ** ** ** ** 
Palm temperature ns ns ** ** ** ** 
Pulse rate ns ns ** ** ns ** 
Breathing rate ns ns ** * ns ** 
 
Placebo, double-distilled water; ns, not significant; *p < 0.05; **p < 0.01. 
 
 





